Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

Rhea-AI Summary

Lariamar Therapeutics (Nasdaq: LRMR) announced its participation in the Guggenheim Genomic Medicines and Rare Disease Days on April 3-4, 2023. The company will engage in a virtual fireside chat and 1x1 investor meetings, showcasing its focus on developing treatments for complex rare diseases.

The fireside chat is scheduled for April 4, 2023, at 4:35 PM ET, accessible via a live webcast link. Following the event, a replay will be available on Larimar's Events and Presentations page. Larimar Therapeutics is advancing its lead compound, CTI-1601, for Friedreich's ataxia and aims to create further treatments for rare diseases through its innovative platform.

BALA CYNWYD, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim Genomic Medicines and Rare Disease Days, which are taking place from April 3 – 4, 2023.

Details on the fireside chat can be found below.

Date:	Tuesday, April 4, 2023
Time:	4:35 PM ET
Webcast Link:	https://kvgo.com/gmrdc/larimar-therapeutics-inc-april-2023

A live webcast of the fireside chat may be accessed using the link above. Following the conclusion of the fireside chat, a replay will be available on the “Events and Presentations” page of Larimar’s website.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:                                                        
Joyce Allaire                                                                
LifeSci Advisors                                                        
jallaire@lifesciadvisors.com                                                 
(212) 915-2569

Company Contact:
Michael Celano        
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is Larimar Therapeutics' participation in the Guggenheim event?

Larimar Therapeutics will participate in a virtual fireside chat and 1x1 investor meetings during the Guggenheim Genomic Medicines and Rare Disease Days on April 3-4, 2023.

When is Larimar's fireside chat scheduled?

The fireside chat is scheduled for April 4, 2023, at 4:35 PM ET.

How can I access the webcast of Larimar's fireside chat?

You can access the live webcast of Larimar's fireside chat using this link: https://kvgo.com/gmrdc/larimar-therapeutics-inc-april-2023.

What is the lead compound developed by Larimar Therapeutics?

Larimar's lead compound is CTI-1601, which is being developed as a potential treatment for Friedreich's ataxia.

Where can I find more information about Larimar Therapeutics?

More information about Larimar Therapeutics can be found on their official website: https://larimartx.com.